The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
12 2022
Historique:
received: 23 03 2022
revised: 12 09 2022
accepted: 10 10 2022
pubmed: 25 10 2022
medline: 29 11 2022
entrez: 24 10 2022
Statut: ppublish

Résumé

Our objective was to determine the negative predictive value (NPV) of preoperative FDG PET/CTfor detecting locoregional nodal disease. The aim was to help inform the decision-making process when identifying patients with early-stage OPSCC that would be suitable for transoral robotic surgery (TORS) as a single-modality treatment. A retrospective cohort study was conducted of adults with primary stage cT1-2 OPSCC with up to one metastatic neck lymph node (cN0-1) planned for TORS. Patients with a preoperative PET/CT and who had undergone staging neck dissection (ND) were included. Clinical and pathological nodal staging was established based on PET/CT and ND, respectively. The primary outcome was the frequency of occult (not seen on PET/CT) nodal disease on ND. Eighty-eight patients were included (N = 88). The rate of occult nodal disease was 28.4 % (n = 25). The NPV of PET/CT in the clinically negative neck was 79 % and 66 % in cases with a single clinical node. Following staging ND, thetreatment plan changed in 27 % of cases overall, 7 % in cN0 and 36.7 % in cN1. Among these, 18 % met criteria for radiotherapy and 9 % for CRT. This represented a decrease in the number of ideal candidates for TORS as single-modality treatment from 88 to 64 (73 %). PET/CT is a useful tool in the workup of patients for primary TORS. However, about one third of patients with early-stage OPSCC might benefit from adjuvant therapy not predicted by preoperative PET/CT. A staging ND helps confirm candidates for single-modality treatment with TORS.

Identifiants

pubmed: 36274346
pii: S1368-8375(22)00502-4
doi: 10.1016/j.oraloncology.2022.106213
pii:
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106213

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mario Tapia (M)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Electronic address: Mtapiac21@gmail.com.

Jamil Manji (J)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of ENT Head & Neck Surgery, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.

Kaman Dhillon (K)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Stephen Kleid (S)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Samuel Flatman (S)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of ENT Head & Neck Surgery, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.

Jessica Prasad (J)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Anthony Cardin (A)

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Tsien Fua (T)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

Danny Rischin (D)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Benjamin Dixon (B)

Pinnacle Surgery, Epworth Richmond Hospital, Melbourne, VIC, Australia; Department of ENT Head & Neck Surgery, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia.

Matthew J R Magarey (M)

Department of Head and Neck Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Pinnacle Surgery, Epworth Richmond Hospital, Melbourne, VIC, Australia; Department of Medical Education, University of Melbourne, Melbourne, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH